Get started
Author

Margit Sandholzer

Observed names: Dr. Margit Sandholzer, M. Sandholzer, Sandholzer, Margit
ORCID: 0009-0004-1893-7245
Observed ORCID: 0009-0004-1893-7245
OpenAlex ID: A5045257898
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
2021 · Simon Peter Gampenrieder, Gabriel Rinnerthaler, et al. · Breast Cancer Research · 146
PDF
Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group
2022 · S.P. Gampenrieder, V. Dezentjé, et al. · ESMO Open · 24
PDF
Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)
2021 · Gabriel Rinnerthaler, Simon Peter Gampenrieder, et al. · Therapeutic Advances in Medical Oncology · 6
PDF
Abstract PO1-05-13: Drop-out rates from line to line of treatment in metastatic breast cancer (MBC): Results from the Austrian AGMT_MBC-Registry
2024 · Simon Gampenrieder, Gabriel Rinnerthaler, et al. · Cancer Research · 4
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
2022 · Gabriel Rinnerthaler, Christian Singer, et al. · Wiener klinische Wochenschrift · 3
PDF
Abstract P1-21-08: Brain metastases (BM) from breast cancer: Real-word data from the Austrian AGMT_MBC-registry
2022 · Simon Peter Gampenrieder, Gabriel Rinnerthaler, et al. · Cancer Research · 2
Abstract PS12-21: First-line treatment of hormone receptor positive metastatic breast cancer (MBC) in everyday practice: Results from the Austrian AGMT_MBC-Registry
2021 · Gabriel Rinnerthaler, Simon P Gampenrieder, et al. · Cancer Research · 2
Central nervous system metastases in metastatic breast cancer: Incidence, subtype-specific patterns, and outcomes from the Austrian AGMT_MBC registry
2026 · Simon Peter Gampenrieder, Vanessa Castagnaviz, et al. · The Breast
PDF
AI-assisted continuous-time modelling of metastatic breast cancer reveals subtype-specific spatiotemporal organ interactions
2026 · Marc Vaisband, Gabriel Rinnerthaler, et al. · medRxiv
Abstract PS1-11-26: Esr1 mutations and use of the oral serd elacestrant in metastatic breast cancer patients in austria: results from the agmt_mbc-registry
2026 · S. P. Gampenrieder, G. Rinnerthaler, et al. · Clinical Cancer Research
Abstract PS5-01-04: Clinical predictors for first-line treatment duration in HER2-positive metastatic breast cancer Results from the AGMT_MBC-Registry
2026 · G. Rinnerthaler, S. P. Gampenrieder, et al. · Clinical Cancer Research
Abstract PS2-04-08: Incidence of second primary tumors and second primary breast cancers events in patients with metastatic breast cancer: results from the Austrian AGMT_MBC-Registry
2026 · V. Castagnaviz, S. P. Gampenrieder, et al. · Clinical Cancer Research
511P Pathogenic ESR1 alterations and co-alterations in HR+/HER2- advanced breast cancer
2025 · N. Dobric, C. Suppan, et al. · Annals of Oncology
Abstract P4-12-09: Cytotoxic treatment and survival after CDK4/6 inhibitors in patients with luminal metastatic breast cancer before the era of anti-body-drug-conjugates: Results from the Austrian AGMT_MBC-Registry
2025 · Gabriel Rinnerthaler, Simon Peter Gampenrieder, et al. · Clinical Cancer Research
Abstract P5-12-07: Increase of repeated biopsies in metastatic breast cancer over time: Results from the Austrian AGMT_MBC-Registry
2025 · Simon Gampenrieder, Gabriel Rinnerthaler, et al. · Clinical Cancer Research
Abstract P1-01-10: Comparison of different gene expression tests in breast cancer: poor correlation of Prosigna, EndoPredict and MammaPrint
2025 · Brigitte Schober, Andreas Bösl, et al. · Clinical Cancer Research
321P Incidence, outcome, and biology of CNS involvement in breast cancer: Results from the Austrian AGMT_MBC-registry
2025 · S.P. Gampenrieder, V. Castagnaviz, et al. · ESMO Open
PDF
Abstract PO4-04-14: Change of first-line treatment pattern in metastatic luminal breast cancer: Results from the Austrian AGMT_MBC-Registry
2024 · Gabriel Rinnerthaler, Simon Gampenrieder, et al. · Cancer Research
Abstract P4-01-27: Prognosis and treatment landscape of HER2-positive metastatic breast cancer (MBC) before the availability of tucatinib and trastuzumab-deruxtecan: Results from the Austrian AGMT_MBC-Registry
2023 · Simon P. Gampenrieder, Gabriel Rinnerthaler, et al. · Cancer Research
Abstract P3-05-49: Number of involved organs at baseline is prognostic for overall survival in patients with metastatic breast cancer: Results from the AGMT_MBC-Registry
2023 · Gabriel Rinnerthaler, Simon P. Gampenrieder, et al. · Cancer Research
Abstract P1-16-03: Response pattern to chemotherapy in metastatic breast cancer (MBC): Real-word data from the Austrian AGMT_MBC-Registry
2022 · Gabriel Rinnerthaler, Simon P Gampenrieder, et al. · Cancer Research
283P Treatment landscape of HER2-positive metastatic breast cancer (MBC): Results from the Austrian AGMT_MBC-Registry
2021 · S.P. Gampenrieder, G. Rinnerthaler, et al. · Annals of Oncology
Abstract PS1-41: Does complete surgical removal of metastases in oligometastatic breast cancer improve survival? A matched-pair analysis of the AGMT_MBC-registry
2021 · Simon Peter Gampenrieder, Gabriel Rinnerthaler, et al. · Cancer Research
JC papovavirus leukencephalopathy in a patient with B-CLL receiving long-term chemotherapy in combination with an anti-CD20-antibody
2009 · B. L. Hartmann, T. Winder, et al. · Journal of Clinical Oncology
Works count: 28
Citation count: 186
H-index: 4
I10-index: 2
Year
Topic
Type